The association between dyslipidaemia and types of antipsychotic medications among patients with chronic schizophrenia.
نویسندگان
چکیده
This cross sectional study aimed to explore the association between dyslipidaemia and types of antipsychotics in 100 patients with chronic schizophrenia. Lipid profile, weight, height and waist circumference together with other relevant factors were measured. We found there was a high rate of dyslipidaemia among patients with chronic schizophrenia treated with antipsychotics (66%), however there was no significant difference found between typical or atypical antipsychotics (OR=1). All sociodemographic and clinical factors were not significantly associated with dyslipidaemia. Only non-Malays were found to have significant dyslipidaemia (p<0.1). Effective management is needed to deal with the dyslipidaemia in this group.
منابع مشابه
Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia
Introduction: Hyperprolactinemia is a common serious side effect of antipsychotic medications that are currently used in the treatment of patients with schizophrenia. Pharmacogenetic approaches offer the possibility of identifying patient-specific biomarkers for predicting the risk of this side effect. We investigated a possible relationship between variants (SNPs) in genes for cytochrome 2D6 (...
متن کاملDetermination Changes of Blood Biomarker Levels in Two Treatment status of Antipsychotic Polypharmacy and Aripiprazole Monotherapy in Patients with Long-Term Schizophrenia
Background and objectives: Schizophrenia is a chronic psychiatric disorder, which reduces the patient quality of life. Despite the recommendation for treating this disorder with a minimum dose of medications, antipsychotic polypharmacy has been used experimentally that cause increasing the drug interactions. Aripiprazole has low risk of metabolic has recommended as a first line a treatment fo...
متن کاملEvaluation of the efficacy and safety of pregabalin as an adjuvant to antipsychotics in patients with chronic schizophrenia: a six-week pilot double-blind placebo-controlled trial
Introduction and objectives: Antipsychotics or dopamine receptor antagonists are the major components of treatment but about 10-20% of patients with schizophrenia do not benefit from treatment with antidopaminergic agents, indicating other neuronal systems may be involved in this disorder (2). Dysregulation of both excitatory and inhibitory mechanisms N-Methyl-D-aspartic acid (NMDA) and γ-Amino...
متن کاملMetabolic Disturbances with Antipsychotic Medication
! Increasing clinical experience with atypical antipsychotics has demonstrated an association between these medications and metabolic disturbances, including hyperglycaemia, diabetes mellitus, weight gain and dyslipidaemia. ! The term metabolic syndrome describes the incidence of a number of interrelated metabolic disturbances occurring in one patient and is becoming increasingly recognised as ...
متن کاملبررسی اثر افزودن نالترکسان به داروهای آنتی سایکوتیک، بر علایم مثبت و منفی بیماران مبتلا به اسکیزوفرنیای مزمن
Background and Purpose: In recent years, review of opioid system and its changes in the psychopathology of schizophrenia through thear probable role our on neuronal synopses and cell body of dopaminergic neurons and also decrease dopamine secretion from acumbans nuclei and effects of opium agonists in treatment of those patients has been adventajes for clinicians. Materials and methods: I...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The Medical journal of Malaysia
دوره 67 1 شماره
صفحات -
تاریخ انتشار 2012